New study tracks safety of prostate cancer drug darolutamide in korean patients
NCT ID NCT06334120
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 27 times
Summary
This study is checking the safety of a drug called darolutamide in Korean men with a type of prostate cancer that hasn't spread or has spread but responds to hormone therapy. The drug works by blocking male hormones that help cancer grow. Researchers will track side effects and see how well the drug works over one year of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Multiple locations
RECRUITINGMultiple Locations, South Korea
Conditions
Explore the condition pages connected to this study.